

# The Role of Imaging with $^{111}\text{In}$ -Ibritumomab Tiuxetan in the Ibritumomab Tiuxetan (Zevalin) Regimen: Results from a Zevalin Imaging Registry

Peter S. Conti, MD, PhD<sup>1</sup>; Christine White, MD<sup>2</sup>; Peter Pieslor, MD<sup>2</sup>; Arturo Molina, MD<sup>2</sup>; Jacqueline Aussie, BA<sup>2</sup>; and Paul Foster, MD<sup>2</sup>

<sup>1</sup>Department of Radiology, University of Southern California, Los Angeles, California; and <sup>2</sup>Global Medical Affairs, Biogen Idec Inc., San Diego, California

The ibritumomab tiuxetan therapeutic regimen consists of a dose of rituximab, 250 mg/m<sup>2</sup>, followed by  $^{111}\text{In}$ -ibritumomab tiuxetan, for imaging, on day 1 and a dose of rituximab followed by  $^{90}\text{Y}$ -ibritumomab tiuxetan, for therapy, on day 7, 8, or 9. Treatment with the Food and Drug Administration–approved regimen also requires that scans be performed at 2–24 h and at 48–72 h after the  $^{111}\text{In}$ -ibritumomab tiuxetan, with an optional third scan at 90–120 h, to confirm appropriate biodistribution. In the clinical trials before the approval of the regimen, only 1 patient (of approximately 400) was not treated with  $^{90}\text{Y}$ -ibritumomab tiuxetan after imaging with  $^{111}\text{In}$ -ibritumomab tiuxetan, because of altered biodistribution. The Zevalin Imaging Registry was established by Biogen Idec Inc. to identify cases of potential altered biodistribution and to collect clinical information in cases in which the regimen was not completed after imaging. **Methods:** The registry surveyed treating physicians to verify completion of treatment with the ibritumomab tiuxetan therapeutic regimen in patients treated with  $^{111}\text{In}$ -ibritumomab tiuxetan between March 27, 2002, and March 31, 2003. **Results:** Survey data were collected on 953 of an estimated 1,144–1,192 patients in whom ibritumomab tiuxetan therapy was initiated (case capture rate of 80%–83%). Thirty-eight cases were reported in which a decision not to treat was made after imaging with  $^{111}\text{In}$ -ibritumomab tiuxetan (4.0% of all cases captured); 16 of these were for imaging reasons, and 22 were for medical reasons. Twelve of the 16 imaging cases met the criteria for altered biodistribution (1.3%). Of these 12 cases, 6 (0.6%) were suspected to be true altered biodistribution and 6 appeared to be due to the use of a procedure for radiolabeling  $^{111}\text{In}$ -ibritumomab tiuxetan that differed from that in the prescribing information. All cases of altered biodistribution were seen on the first image (2–24 h) after the administration of  $^{111}\text{In}$ -ibritumomab tiuxetan. The 22 cases in which decisions not to treat were made for medical reasons accounted for 2.3% of the cases. The majority of these cases (19/22) were in patients who had an expected biodistribution but had a rapid change in their clinical

condition that precluded treatment. **Conclusion:** The rate of true altered biodistribution was 0.6% in the Zevalin Imaging Registry, which collected treatment decisions based on data from approximately 80% of all patients treated commercially in the first year after drug approval. All cases of altered biodistribution were apparent on the first image, obtained at 2–24 h after the administration of  $^{111}\text{In}$ -ibritumomab tiuxetan.

**Key Words:** radioimmunotherapy; ibritumomab tiuxetan; imaging; biodistribution

**J Nucl Med 2005; 46:1812–1818**

In February 2002,  $^{90}\text{Y}$ -Ibritumomab tiuxetan was approved in the United States. It is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed non-Hodgkin's lymphoma (NHL), including patients with rituximab-refractory NHL (1). Clinical data indicate that  $^{90}\text{Y}$ -ibritumomab tiuxetan is an effective therapy for NHL. Designed to exploit the inherent radiosensitivity of lymphomas, the regimen can produce high rates of overall response (73%–83%) and long-term responses (time to progression  $\geq 12$  mo; 37%) in patients with CD20+ B-cell NHL (2–7). Responses of  $> 6$  y duration have been observed in some patients (6). In addition, the overall response rates and durations of response are greater when  $^{90}\text{Y}$ -ibritumomab tiuxetan is used early in the course of treatment ( $\leq 2$  prior chemotherapies or at first relapse) (8). There is evidence that the regimen is effective as a frontline therapy for follicular lymphoma, either in combination with short-course chemotherapy (9) or as a single agent followed by rituximab maintenance (10), and in relapsed aggressive lymphomas (11). Treatment with  $^{90}\text{Y}$ -ibritumomab tiuxetan does not seem to have any effect on the efficacy or safety of other treatments that are used after relapse (12–14).

In the United States treatment with the ibritumomab tiuxetan therapeutic regimen begins on day 1 with an infusion of rituximab, 250 mg/m<sup>2</sup>, followed within 4 h by an

Received May 4, 2005; revision accepted Aug. 8, 2005.

For correspondence or reprints contact: Peter S. Conti, MD, PhD, Department of Radiology, University of Southern California, 1510 San Pablo St., Suite 350, Los Angeles, CA 90033.

E-mail: pconti@usc.edu

intravenous injection of an imaging dose of  $^{111}\text{In}$ -ibritumomab tiuxetan, 185 MBq (5 mCi). Two imaging scans are acquired at 2–24 h and at 48–72 h after  $^{111}\text{In}$ -ibritumomab tiuxetan, with an optional third scan at 90–120 h. On day 7, 8, or 9, patients are given an infusion of rituximab, 250 mg/m<sup>2</sup>, followed by an intravenous injection of  $^{90}\text{Y}$ -ibritumomab tiuxetan given over 10 min. The dose of  $^{90}\text{Y}$ -ibritumomab tiuxetan is 11.1 or 14.8 MBq/kg (0.3 or 0.4 mCi/kg) depending on platelet count, with a maximum total dose of 1,184 MBq (32 mCi).

The  $\gamma$ -emitting radioisotope  $^{111}\text{In}$  was used in the clinical development of the ibritumomab tiuxetan regimen for measuring organ-specific accumulation and for determining whether dosimetry before treatment with  $^{90}\text{Y}$ -ibritumomab tiuxetan was required (15,16).

Central dosimetry analysis, performed in 179 patients using regions of interest for 5 organs (liver, lungs, kidney, spleen, and sacral marrow), showed that the radiation-absorbed doses were estimated to be below the maximum allowable 2,000 cGy to uninvolved normal organs and 300 cGy to the red marrow (17). It was also determined that there was no correlation between the estimated total-body or red-marrow radiation-absorbed doses and the nadirs of the absolute neutrophil count, platelet count, or hemoglobin level.

Routine dosimetry is not required with the ibritumomab tiuxetan regimen, because of a lack of correlation between the estimated radiation-absorbed dose and hematologic toxicity, the predictable urinary clearance of  $^{90}\text{Y}$ -ibritumomab tiuxetan, and the absence of dehalogenation (16,17). Imaging with  $^{111}\text{In}$ -ibritumomab tiuxetan continues, however, as an additional measure to detect any potential altered biodistribution issues that were not seen in the clinical trials. Expected and altered biodistribution, as described in the prescribing information, are presented in Table 1. Whole-body  $\gamma$ -camera images of the expected biodistribution are

shown in Figure 1. Only 1 of 400 patients who underwent imaging in the clinical trials was not treated with  $^{90}\text{Y}$ -ibritumomab tiuxetan because of altered biodistribution. A Zevalin Imaging Registry was established to identify cases of potential altered biodistribution in U.S. commercial use of the regimen, investigating the frequency of patients who were imaged with  $^{111}\text{In}$ -ibritumomab tiuxetan but were not then treated with  $^{90}\text{Y}$ -ibritumomab tiuxetan, the reasons for their not being treated, the patterns of altered biodistribution, and the utility of imaging in guiding treatment decisions. Reported here are the incidence of altered biodistribution and the reasons for not proceeding to treatment with  $^{90}\text{Y}$ -ibritumomab tiuxetan as collected by the Zevalin Imaging Registry.

## MATERIALS AND METHODS

### Registry Design

The Zevalin Imaging Registry was established by Biogen Idec Inc. to identify cases of potential altered biodistribution and to collect additional clinical information in cases in which the treatment regimen was not completed after imaging with  $^{111}\text{In}$ -ibritumomab tiuxetan in the commercial setting. Data were collected on patients treated from March 27, 2002, through March 31, 2003. Participation in the registry by the treating physician was voluntary, and, in cases in which clinical information was collected on no-treatment decisions, the clinical information was de-identified.


The initial mailing, consisting of a letter explaining the purpose of the registry and registry data forms, was sent to approximately 4,000 nuclear medicine physicians, radiation oncologists, and chief technicians or technologists of nuclear medicine. The mailing list was acquired from the Society of Nuclear Medicine.

Data about the shipments of ibritumomab tiuxetan kits were used to identify the medical treatment centers that ordered the therapy. Registry staff contacted all of the treating physicians and requested their participation in the registry. Registry data form 1 and the standard cover letter explaining the purpose of the registry were then sent to each treatment center. If the patient had been

**TABLE 1**  
Expected Biodistribution and Altered Biodistribution on Whole-Body  $\gamma$ -Images

Biodistribution	Description
Expected	<p>Visual inspections of <math>\gamma</math>-images for expected biodistribution show the following:</p> <ul style="list-style-type: none"> <li>• Easily detectable uptake in blood-pool areas on first image, with less activity in blood-pool areas on second or third image</li> <li>• Moderately high or high uptake in normal liver and spleen during first and second or third image</li> <li>• Moderately low or very low uptake in normal kidneys, lungs, urinary bladder, and normal bowel on first and second or third image</li> <li>• Localization to lymphoid aggregates in bowel wall has been reported</li> <li>• Tumor uptake may be visualized in soft tissues as areas of increased intensity, and tumor-bearing areas in normal organs may be seen as areas of increased or decreased intensity</li> </ul>
Altered	<p>Criteria for altered biodistribution are met if any of the following is detected upon inspection of <math>\gamma</math>-images:</p> <ul style="list-style-type: none"> <li>• Rapid clearance of radioimmunoconjugate from blood pool, with prominent liver, spleen, or marrow uptake on first image</li> <li>• Diffuse uptake in normal lung more intense than cardiac blood pool on first image or more intense than liver on second or third image</li> <li>• Kidneys with greater intensity than liver on posterior view of second or third image</li> <li>• Intense areas of uptake throughout normal bowel comparable to uptake by liver on second or third image</li> </ul>

**FIGURE 1.** Whole-body  $\gamma$ -camera images obtained at 4 and 68 h after administration of  $^{111}\text{In}$ -ibritumomab tiuxetan, showing expected biodistribution, with the radiopharmaceutical easily detectable in the blood-pool areas on 4-h images. Moderately high or high uptake in normal liver and spleen is seen on 4- and 68-h images, and moderately low or very low uptake in normal kidneys, urinary bladder, and bowel is seen on 4- and 68-h images. Tumor uptake is seen in mediastinal lymph nodes. (Reprinted with permission of Biogen Idec Inc.)



treated with  $^{90}\text{Y}$ -ibritumomab tiuxetan after imaging, no further information was requested. However, if the patient had not been treated with  $^{90}\text{Y}$ -ibritumomab tiuxetan after the  $^{111}\text{In}$ -ibritumomab tiuxetan, registry data form 2 was sent to the treatment center to query the reasons for the decision not to treat and to request copies of the whole-body images. If a treatment site did not return the data forms, verbal confirmation of the completion of therapy with the ibritumomab tiuxetan regimen and the date of administration were obtained.

#### Estimation of Number of Patients Treated

Biogen Idec Inc. customer service supplied the number of ibritumomab tiuxetan imaging and therapy kits that had been shipped. The maximum number of patients imaged was estimated as the number of imaging kits shipped minus the number of kits that were not used. The minimum number of patients imaged was estimated as the number of paired (imaging and therapy) kits that were shipped plus the number of no-treatment decisions captured by the registry.

## RESULTS

### Treatment Information

A total of 1,212 imaging kits and 1,161 therapy kits were shipped between March 27, 2002, and March 31, 2003, and 20 of the imaging kits were reported not to have been used. The estimated number of paired kits that were shipped and for which an isotope shipment could be reconciled was 1,106. The registry found 38 cases in which a patient was imaged with  $^{111}\text{In}$ -ibritumomab tiuxetan but was not treated with  $^{90}\text{Y}$ -ibritumomab tiuxetan. From these figures, the maximum number of patients who may have initiated therapy was 1,192 (1,212 imaging kits shipped minus the 20 kits that were reported not to have been used). The minimum number of patients who began therapy was 1,144 (1,106

paired kits shipped with isotopes plus the 38 cases with no-treatment decisions).

### Registry Participation and Rate of No-Treatment Decisions

Approximately 340 nuclear medicine specialists participated in the registry and provided information on 953 patients. The case capture rate with an estimated 1,144–1,192 patients was 80%–83%. No-treatment decisions were made based on imaging decisions in 16 cases and on medical reasons in 22 cases. The rate of no-treatment decisions was 4.0% (Table 2).

### No-Treatment Decisions Due to Imaging Reasons

Physicians decided not to treat with  $^{90}\text{Y}$ -ibritumomab tiuxetan in 16 cases (15 patients) because of images that were interpreted as indicating altered biodistribution. All cases of altered biodistribution were detected on scan 1, obtained at 2–24 h after the administration of  $^{111}\text{In}$ -ibritumomab tiuxetan. Twelve of these 16 cases met the criteria for altered biodistribution according to the prescribing in-

**TABLE 2**  
Patients Imaged with  $^{111}\text{In}$ -Ibritumomab Tiuxetan But Not Treated with  $^{90}\text{Y}$ -Ibritumomab Tiuxetan

Reason	No. (%) of patients not treated with $^{90}\text{Y}$ -Ibritumomab tiuxetan
Imaging	16 (1.7)
Medical	22 (2.3)
Total	38 (4.0)

Survey data were collected on 953 patients.

formation: 6 (0.6%) of them appeared to result from the use of a procedure for radiolabeling  $^{111}\text{In}$ -ibritumomab tiuxetan that deviated from that in the prescribing information and 6 cases were suspected to be true altered biodistribution (Table 3).

**Altered Biodistribution Due to a Radiolabeling Procedure that Was Inconsistent with the Prescribing Information.** Six patients (7 cases) had an indium scan pattern consistent with altered biodistribution that involved increased renal uptake. Upon investigation, it was found that treatment with  $^{90}\text{Y}$ -ibritumomab tiuxetan in at least 6 of the 7 cases of renal uptake would not have resulted in greater risk to the patient, because the altered biodistribution was due to a specific  $^{111}\text{In}$ -ibritumomab tiuxetan radiolabeling issue. This conclusion is substantiated by the following observations. First, 6 cases involved a single nuclear pharmacy chain that used an alternative radiolabeling method for  $^{111}\text{In}$ -ibritumomab tiuxetan. This alternative radiolabeling procedure consisted of a change in the amount of formulation buffer added after the radiolabeling reaction incubation. In addition, in some of these 6 cases, a glass syringe rather than a plastic syringe was used during the radiolabeling procedure or there was a failure to use a cool pack in the transportation of  $^{111}\text{In}$ -ibritumomab tiuxetan. Second, 3 of the patients who had abnormal renal uptake were subsequently given  $^{111}\text{In}$ -ibritumomab tiuxetan prepared at a different nuclear pharmacy. They then showed expected biodistribution and completed  $^{90}\text{Y}$ -ibritumomab tiuxetan treatment without reported adverse events. Finally, no further cases of altered biodistribution with a renal uptake pattern were captured in the registry after the implicated nuclear pharmacy chain began following the U.S. prescribing information method for radiolabeling  $^{111}\text{In}$ -ibritumomab tiuxetan. In the 1 additional case of renal uptake that did not involve the nuclear pharmacy chain, renal pathology could not be ruled out, because of a lack of clinical information from the site. However, the images collected in this case were similar to those observed in the other cases of altered renal biodistribution, and it is thought

to be likely that this case was also the result of an isolated  $^{111}\text{In}$ -ibritumomab tiuxetan radiolabeling issue.

**True Altered Biodistribution.** True altered biodistribution was suspected in only 6 cases (0.6%): 4 cases of prominent bone marrow uptake, 1 case of pneumonia that was seen on chest x-ray before imaging, and 1 case of increased renal uptake in which there was insufficient information to rule out a disease-related cause (described above). Images of a case of prominent bone marrow uptake and the case of increased renal uptake are shown in Figure 2. The images in the cases of prominent bone marrow uptakes were characterized by uptake in the proximal humeri, sternum, ribs, vertebral bodies, iliac crest, and proximal femurs. Two patients also had uptake in the distal long bones. The disease characteristics and treatment history varied considerably among these patients, making it difficult to determine the cause of the prominent bone marrow uptake (Table 4), and it was likely tumor related. Two patients with prominent bone marrow uptake also had prominent splenic uptake; because no splenic uptake was seen in the 2 other cases, it is likely that these patients had had splenectomies. Lymphomatous bone marrow involvement was diagnosed in 2 patients—20% involvement in 1 and not specified in the other (Table 4). No information on bone marrow involvement was available on the third patient. The documentation of bone marrow involvement in this setting is likely less rigorous than that in the clinical trial setting (bilateral biopsies required in the clinical trials) and may explain why bone marrow uptake was seen on imaging without known involvement by biopsy. Because dosimetry was not performed, it is not possible to determine the estimated radiation-absorbed doses to the red marrow and whether they may have exceeded 300 cGy had  $^{90}\text{Y}$ -ibritumomab tiuxetan been administered.

The final case of suspected true altered biodistribution was in a patient with a left lower lobe infiltrate that was evident on chest x-ray before the delivery of  $^{111}\text{In}$ -ibritumomab tiuxetan. The first posterior images showed greater uptake in the left lower lobe than in the liver or spleen. There was, however, no evidence of tumor in the left lower lobe on CT or  $^{18}\text{F}$ -FDG PET. Because the patient had clinical and radiographic evidence of active pneumonia, the altered biodistribution was likely related to the infection.


**Other Cases of Altered Biodistribution.** The remaining 4 cases of suspected altered biodistribution were due to misinterpretation of the images or criteria for altered biodistribution. Evaluation of the images in 3 of these cases showed that they did not meet the criteria for altered biodistribution as described in the prescribing information. The decisions not to treat were incorrectly based on the appearance of  $^{111}\text{In}$ -ibritumomab tiuxetan in the bowel or the lack of tumor uptake.

The images in the final case showed a small pleural effusion that led to the decision not to treat. This patient's images were not provided to the registry, and it is not clear from the clinical information provided whether the criteria

**TABLE 3**  
Imaging Reasons for Not Treating Patients with  
 $^{90}\text{Y}$ -Ibritumomab Tiuxetan

Reason	No.
Suspected true altered biodistribution	
Prominent bone marrow uptake	4
High renal uptake	1
Pneumonia	1
Altered biodistribution suspected to be due to improper radiolabeling	
Renal uptake	6
Criteria for altered biodistribution not met	
Criteria for altered biodistribution in prescribing information misinterpreted	3
Pleural effusion	1
Total	16





**FIGURE 2.** Whole-body  $\gamma$ -camera images of representative patients obtained at 24 h after administration of  $^{111}\text{In}$ -ibritumomab tiuxetan (A), showing prominent bone marrow and splenic uptake, and at 3 and 48 h after administration of  $^{111}\text{In}$ -ibritumomab tiuxetan (B), showing greater than expected renal uptake. (Reprinted with permission of Biogen Idec Inc.)

for altered biodistribution were met. It is not likely, however, that treatment in this patient would have resulted in a greater risk of toxicity because the adverse events were not greater in patients with small pleural effusions treated in the clinical trials.

**No-Treatment Decisions Due to Medical Reasons.** The decisions not to treat were for medical reasons in 22 cases (2.3%). These cases can be divided into 3 categories: contraindications to ibritumomab tiuxetan that were found after imaging ( $n = 2$ ), expected biodistribution on imaging but a rapid change in clinical condition that precluded treatment

( $n = 19$ ), and physician decision not to treat outside the labeled indication ( $n = 1$ ). The medical reasons for not proceeding with treatment with  $^{90}\text{Y}$ -ibritumomab tiuxetan are given in Table 5.

## DISCUSSION

The Zevalin Imaging Registry captured data on 953 of an estimated 1,144–1,192 patients who began ibritumomab tiuxetan therapy between March 27, 2002, and March 31, 2003. Decisions not to treat were made in 38 cases (4.0%),

**TABLE 4**  
Characteristics of Patients with Prominent Bone Marrow Uptake

Characteristic	Patient 1*	Patient 2†	Patient 3‡	Patient 4§
Marrow involvement	Yes, % not reported	NR	20%	No
Spleen visualized	Yes, intense	Yes, intense	No	No
Tumor visualized	Yes	Yes	No	No
Blood pool visualized	No on 24-h image	No	Yes on 3-h image	No on 24-h image
Human antimouse antibody	Negative	NR	NR	Negative
Cytotoxic chemotherapy	Ifosfamide, etoposide, carboplatin 10 wk earlier	NR	Fludarabine 8 mo earlier	Cisplatin, cytarabine 3 mo earlier
Granulocyte colony-stimulating factor use	10 wk earlier	NR	NR	No
Interleukin use	9 wk earlier	NR	NR	No
Erythropoietin use	No	Yes, up to time of scan	NR	No

\*Small lymphocytic lymphoma.  
†NHL of unknown histology.  
‡Diffuse follicular center cell NHL.  
§Large noncleaved follicular center cell NHL.  
NR = not reported.

**TABLE 5**Patients Not Treated with  $^{90}\text{Y}$ -Ibritumomab Tiuxetan for Medical Reasons

Reason	No.
Contraindication	2
Marrow fibrosis	1
Prior stem cell transplantation	1
Change in medical condition	19
Disease progression, death	6
Radiation pneumonitis vs. pulmonary infiltrates	1
Rituximab infusion reaction	3
Sepsis, death	1
Severe tumor pain	1
Thrombocytopenia	6
Neutropenia	1
Other	1
Physician refusal to treat off label and off protocol (central nervous system lymphoma)	

for imaging reasons in 16 cases and for medical reasons in 22 cases. All cases of altered biodistribution were seen on the first images, obtained at 2–24 h after the administration of  $^{111}\text{In}$ -ibritumomab tiuxetan. Altered biodistribution was not reported in any of the 22 patients in whom  $^{90}\text{Y}$ -ibritumomab tiuxetan was withheld for medical reasons. There were only 6 cases of suspected true altered biodistribution (0.6%). These were 4 cases of prominent bone marrow uptake, 1 case of pneumonia that was seen on chest x-ray before imaging, and 1 case of increased renal uptake in which there was insufficient information to rule out a disease cause. Only the 4 cases of bone marrow uptake appear to be true altered biodistribution that could not be predicted from the clinical status of the patient. Information on the extent of bone marrow involvement in 1 of these patients was not available, however, and it is not known whether it exceeded that in the patients in the clinical trials (only patients with <25% marrow lymphoma were eligible). Consequently, bone marrow aspirate and biopsy could have excluded this patient from treatment with the ibritumomab tiuxetan therapeutic regimen. The single case of altered biodistribution detected in clinical trials occurred in a patient with hydronephrosis. Although this patient had adequate renal function (i.e., serum creatinine  $\leq 2.0$  mg/dL) at baseline, imaging scans showed more intense uptake of  $^{111}\text{In}$ -ibritumomab tiuxetan in the kidneys than in the liver. As a result, the patient did not proceed to the therapeutic dose.

In rare instances, the imaging component of ibritumomab tiuxetan therapy may have provided an added safety measure. The analysis of the imaging scans resulted in the detection of a  $^{111}\text{In}$ -ibritumomab tiuxetan radiolabeling procedure that deviated from that in the U.S. prescribing information and led to opportunities for educating physicians on interpreting the images correctly. The images also showed 4 cases of altered biodistribution that involved prominent bone marrow uptake and was possibly disease related. In the

absence of a surrogate marker or a clear assessment of bone marrow involvement that would identify candidates for therapy with ibritumomab tiuxetan, the imaging component can help prevent the delivery of excessive radiation to the bone marrow. Because patients with suspected disease-related altered biodistribution did not proceed to treatment with  $^{90}\text{Y}$ -ibritumomab tiuxetan, however, it is not known whether such treatment would have resulted in adverse events. It is possible that effective therapy was withheld from these patients.

## CONCLUSION

These findings confirm that true altered biodistribution is rare (<0.6% of cases) in patients who are treated with the ibritumomab tiuxetan therapeutic regimen in the commercial setting. It is notable that all cases of altered biodistribution documented in this registry and that the 1 case in the clinical trials was seen on the first images. Because of these findings, the current U.S. imaging requirement for therapy with ibritumomab tiuxetan could be changed to a single scan at 2–24 h after the  $^{111}\text{In}$ -ibritumomab tiuxetan, with optional scans at 48–72 h and at 90–120 h as necessary to resolve ambiguities.  $^{90}\text{Y}$ -Ibritumomab tiuxetan is routinely administered in many European countries without biodistribution studies. The European clinical trials in which the regimen was used without  $^{111}\text{In}$ -ibritumomab tiuxetan and imaging have not reported any new safety signals (18,19). Simplifying the imaging requirement would reduce the costs and complexity of treatment with ibritumomab tiuxetan in the United States, thereby making this important therapeutic modality available to more patients with B-cell NHL.

## ADDENDUM

At the time of manuscript submission, the prescribing information for the ibritumomab tiuxetan therapeutic regimen required that 2 whole-body  $\gamma$ -scans be performed to confirm the biodistribution of  $^{111}\text{In}$ -ibritumomab tiuxetan. In August 2005, however, the Food and Drug Administration approved a revision to the prescribing information, reducing the required number of scans. This revision indicates that only 1 whole-body  $\gamma$ -scan is now required and should be administered 48–72 h after the imaging dose of  $^{111}\text{In}$ -ibritumomab tiuxetan. Optional subsequent scans may be performed to resolve ambiguities.

## ACKNOWLEDGMENTS

The authors thank Chao-Hsu John Liu, Jeffrey Feinstein, Thomas Ryskamp, Gene Menendez, V. Douglas Harrough, and Dan Matso for their assistance in preparing this article. Disclosure of financial support: Dr. Conti is a consultant to Biogen Idec Inc., Siemens, and Molecular Imaging Corp., and he has received honoraria from Biogen Idec Inc. and Schering AG. Dr. White, Dr. Pieslor, Dr. Molina, Ms.

Aussie, and Dr. Foster are employees and stockholders of Biogen Idec Inc.

## REFERENCES

1. Zevalin (ibritumomab tiuxetan) [package insert]. San Diego, CA: Biogen Idec Inc; 2005.
2. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. *J Clin Oncol*. 1999;17:3793–3803.
3. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. *Blood*. 2002;99:4336–4342.
4. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. *J Clin Oncol*. 2002;20:3262–3269.
5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol*. 2002;20:2453–2463.
6. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. *Blood*. 2004;103:4429–4431.
7. Witzig TE, Molina A, Gordon LI, et al. Yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) induces durable remissions in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): analysis of long-term responders [abstract]. *Blood*. 2003;102:407a.
8. Emmanouilides C, Murray JL, Vo K, et al. Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma (NHL): results with second-line therapy [abstract]. *Blood*. 2003;102:306b–307b.
9. Shipley DL, Spiegel DR, Carrell DL, Dannaher C, Greco FA, Hainsworth JD. Phase II trial of rituximab and short duration chemotherapy followed by <sup>90</sup>Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial [abstract]. *Proc Am Soc Clin Oncol*. 2004;23:560.
10. Sweetenham JW, Dicke K, Arcaroli J, Kogel K, Rana TM, Rice LL. Efficacy and safety of yttrium 90 (<sup>90</sup>Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma [abstract]. *Blood*. 2004;104:720a.
11. Oki Y, Pro B, Delpassand E, et al. A phase II study of yttrium 90 (<sup>90</sup>Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract]. *Blood*. 2004;104:720a.
12. Schilder RJ, Witzig T, Gordon L, et al. <sup>90</sup>Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma [abstract]. *Proc Am Soc Clin Oncol*. 2002;21:267a.
13. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. *J Clin Oncol*. 2002;20:3885–3890.
14. Ansell SM, Schilder RJ, Pieslor PC, et al. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. *Clin Lymphoma*. 2004;5:202–204.
15. Wagner HN Jr, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with <sup>90</sup>Y-labeled anti-CD20 monoclonal antibody. *J Nucl Med*. 2002;43:267–272.
16. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *Crit Rev Oncol Hematol*. 2001;39:181–194.
17. Wiseman GA, Kommeh E, Leigh B, et al. Radiation dosimetry results and safety correlations from <sup>90</sup>Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. *J Nucl Med*. 2003;44:465–474.
18. Radford JA, Ketterer N, Sebban C, et al. Ibritumomab tiuxetan (Zevalin) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: interim analysis for safety of a multicenter, phase III clinical trial [abstract]. *Blood*. 2003;102:408a.
19. Morschhauser F, Huglo D, Martinelli G, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial [abstract]. *Blood*. 2004;104:41a.



The Journal of  
NUCLEAR MEDICINE

## **The Role of Imaging with $^{111}\text{In}$ -Ibritumomab Tiuxetan in the Ibritumomab Tiuxetan (Zevalin) Regimen: Results from a Zevalin Imaging Registry**

Peter S. Conti, Christine White, Peter Pieslor, Arturo Molina, Jacqueline Aussie and Paul Foster

*J Nucl Med.* 2005;46:1812-1818.

---

This article and updated information are available at:  
<http://jnm.snmjournals.org/content/46/11/1812>

---

Information about reproducing figures, tables, or other portions of this article can be found online at:  
<http://jnm.snmjournals.org/site/misc/permission.xhtml>

Information about subscriptions to JNM can be found at:  
<http://jnm.snmjournals.org/site/subscriptions/online.xhtml>

*The Journal of Nuclear Medicine* is published monthly.  
SNMMI | Society of Nuclear Medicine and Molecular Imaging  
1850 Samuel Morse Drive, Reston, VA 20190.  
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2005 SNMMI; all rights reserved.